风湿免疫科

订阅

MedSci主页 / 所有栏目 / 风湿免疫科

辉瑞的Xeljanz治疗牛皮癣性关节炎获得欧盟批准

2018-07-01 MedSci MedSci原创

辉瑞的Xeljanz牛皮癣性关节炎
关注

欧盟委员会已批准辉瑞公司的Xeljanz作为银屑病关节炎（PsA）的一种治疗方法，显着扩大了该药的范围。欧洲监管机构允许每日两次使用Xeljanz（tofacitinib柠檬酸盐）5mg与甲氨蝶呤联合用于治疗反应不足或不能耐受先前改善疾病的抗风湿药物（DMARD）治疗的成人中的活性PsA。该决定使患者有机会获得新的治疗方法，因为该药是第一种也是唯一一种口服Janus激酶（JAK）抑制剂，将在欧盟批

欧盟委员会已批准辉瑞公司的Xeljanz作为银屑病关节炎（PsA）的一种治疗方法，显着扩大了该药的范围。

欧洲监管机构允许每日两次使用Xeljanz（tofacitinib柠檬酸盐）5mg与甲氨蝶呤联合用于治疗反应不足或不能耐受先前改善疾病的抗风湿药物（DMARD）治疗的成人中的活性PsA。

该决定使患者有机会获得新的治疗方法，因为该药是第一种也是唯一一种口服Janus激酶（JAK）抑制剂，将在欧盟批准用于治疗该病，该病影响该地区150至300万人。

批准来自III期口服银屑病关节炎试验(OPAL)临床开发项目的数据，该方案在美国风湿病学会20 (ACR20)的反应和从健康评估问卷-残疾指数(HAQ-DI)评分的基线变化上有显著的统计学意义。

在OPAL Broaden中，每天两次服用Xeljanz 5mg的患者中有50％达到ACR20应答，而安慰剂组为33％，而在OPAL Beyond中，50％的患者每天两次使用Xeljanz 5mg达到ACR20应答，而给予安慰剂的人中，应答率为24％。

辉瑞公司还指出，在两项研究中，治疗组与安慰剂组在第2周时记录到ACR20反应的统计学显著改善，从而达到次要终点。

法国法兰克福歌德大学和Fraunhofer IME-Translational Medicine＆Pharmacology的风湿病学专家Frank Behrens评论说："这项对Xelzanz的批准对银屑病关节炎社区来说是一个重要的里程碑，他们需要额外的口服治疗方案来帮助控制病情。

Xeljanz最初于去年3月在欧洲被批准用于治疗类风湿性关节炎。


此文系梅斯医学（MedSci)原创整理编译，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1265749, encodeId=e3b81265e49b0, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321077, encodeId=779313210e7f9, content=<a href='/topic/show?id=2a136e77095' target=_blank style='color:#2F92EE;'>#牛皮癣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67770, encryptionId=2a136e77095, topicName=牛皮癣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562077, encodeId=03a615620e750, content=<a href='/topic/show?id=67431881160' target=_blank style='color:#2F92EE;'>#Xeljanz#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18811, encryptionId=67431881160, topicName=Xeljanz)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d3515256947, createdName=839640783, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589991, encodeId=349e1589991c9, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328446, encodeId=20d63284461e, content=好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jul 01 11:56:40 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328436, encodeId=d8a332843610, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Jul 01 11:37:42 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
    2018-07-03 lmm397

    #关节炎#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1265749, encodeId=e3b81265e49b0, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321077, encodeId=779313210e7f9, content=<a href='/topic/show?id=2a136e77095' target=_blank style='color:#2F92EE;'>#牛皮癣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67770, encryptionId=2a136e77095, topicName=牛皮癣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562077, encodeId=03a615620e750, content=<a href='/topic/show?id=67431881160' target=_blank style='color:#2F92EE;'>#Xeljanz#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18811, encryptionId=67431881160, topicName=Xeljanz)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d3515256947, createdName=839640783, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589991, encodeId=349e1589991c9, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328446, encodeId=20d63284461e, content=好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jul 01 11:56:40 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328436, encodeId=d8a332843610, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Jul 01 11:37:42 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
    2018-07-03 yangfl06

    #牛皮癣#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1265749, encodeId=e3b81265e49b0, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321077, encodeId=779313210e7f9, content=<a href='/topic/show?id=2a136e77095' target=_blank style='color:#2F92EE;'>#牛皮癣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67770, encryptionId=2a136e77095, topicName=牛皮癣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562077, encodeId=03a615620e750, content=<a href='/topic/show?id=67431881160' target=_blank style='color:#2F92EE;'>#Xeljanz#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18811, encryptionId=67431881160, topicName=Xeljanz)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d3515256947, createdName=839640783, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589991, encodeId=349e1589991c9, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328446, encodeId=20d63284461e, content=好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jul 01 11:56:40 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328436, encodeId=d8a332843610, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Jul 01 11:37:42 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
    2018-07-03 839640783

    #Xeljanz#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1265749, encodeId=e3b81265e49b0, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321077, encodeId=779313210e7f9, content=<a href='/topic/show?id=2a136e77095' target=_blank style='color:#2F92EE;'>#牛皮癣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67770, encryptionId=2a136e77095, topicName=牛皮癣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562077, encodeId=03a615620e750, content=<a href='/topic/show?id=67431881160' target=_blank style='color:#2F92EE;'>#Xeljanz#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18811, encryptionId=67431881160, topicName=Xeljanz)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d3515256947, createdName=839640783, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589991, encodeId=349e1589991c9, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328446, encodeId=20d63284461e, content=好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jul 01 11:56:40 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328436, encodeId=d8a332843610, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Jul 01 11:37:42 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
    2018-07-03 chenwq14

    #欧盟批准#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1265749, encodeId=e3b81265e49b0, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321077, encodeId=779313210e7f9, content=<a href='/topic/show?id=2a136e77095' target=_blank style='color:#2F92EE;'>#牛皮癣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67770, encryptionId=2a136e77095, topicName=牛皮癣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562077, encodeId=03a615620e750, content=<a href='/topic/show?id=67431881160' target=_blank style='color:#2F92EE;'>#Xeljanz#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18811, encryptionId=67431881160, topicName=Xeljanz)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d3515256947, createdName=839640783, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589991, encodeId=349e1589991c9, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328446, encodeId=20d63284461e, content=好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jul 01 11:56:40 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328436, encodeId=d8a332843610, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Jul 01 11:37:42 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
    2018-07-01 医者仁心5538

    好消息

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1265749, encodeId=e3b81265e49b0, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321077, encodeId=779313210e7f9, content=<a href='/topic/show?id=2a136e77095' target=_blank style='color:#2F92EE;'>#牛皮癣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67770, encryptionId=2a136e77095, topicName=牛皮癣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562077, encodeId=03a615620e750, content=<a href='/topic/show?id=67431881160' target=_blank style='color:#2F92EE;'>#Xeljanz#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18811, encryptionId=67431881160, topicName=Xeljanz)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d3515256947, createdName=839640783, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589991, encodeId=349e1589991c9, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Jul 03 00:54:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328446, encodeId=20d63284461e, content=好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jul 01 11:56:40 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328436, encodeId=d8a332843610, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Jul 01 11:37:42 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
    2018-07-01 龙胆草

    学习谢谢分享

    0